PURPOSE: Early after therapy, 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) imaging is not always reliable due to the influx of inflammatory cells while apoptosis imaging offers a direct and early measurement of therapy effects. This study uses an improved apoptosis probe ((99m)Tc-hAnxA5) in combination with [(18)F]FDG imaging to evaluate therapy response. PROCEDURES: Daudi tumor tissue was implanted in the spleen of SCID mice. Treatment was performed with adriamycin and cyclophosphamide. Sequential [(18)F]FDG-positron emission tomography (PET) was acquired over 6 days and (99m)Tc-hAnxA5-SPECT was performed before and 1 day after therapy. RESULTS: On day 1, therapy induced apoptosis was visualized with (99m)Tc-hAnxA5 without a measurable change in [(18)F]FDG uptake. [(18)F]FDG uptake decreased significantly on day 3 and was even more pronounced on day 6. CONCLUSION: In this preclinical model, (99m)Tc-hAnxA5 imaging was able to detect apoptosis before metabolic changes were measured. These results confirm the value of apoptosis imaging for therapy response and give more insight in [(18)F]FDG imaging and its parameters to evaluate response.
PURPOSE: Early after therapy, 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) imaging is not always reliable due to the influx of inflammatory cells while apoptosis imaging offers a direct and early measurement of therapy effects. This study uses an improved apoptosis probe ((99m)Tc-hAnxA5) in combination with [(18)F]FDG imaging to evaluate therapy response. PROCEDURES: Daudi tumor tissue was implanted in the spleen of SCIDmice. Treatment was performed with adriamycin and cyclophosphamide. Sequential [(18)F]FDG-positron emission tomography (PET) was acquired over 6 days and (99m)Tc-hAnxA5-SPECT was performed before and 1 day after therapy. RESULTS: On day 1, therapy induced apoptosis was visualized with (99m)Tc-hAnxA5 without a measurable change in [(18)F]FDG uptake. [(18)F]FDG uptake decreased significantly on day 3 and was even more pronounced on day 6. CONCLUSION: In this preclinical model, (99m)Tc-hAnxA5 imaging was able to detect apoptosis before metabolic changes were measured. These results confirm the value of apoptosis imaging for therapy response and give more insight in [(18)F]FDG imaging and its parameters to evaluate response.
Authors: K Itoh; T Ohtsu; Y Sasaki; M Ogura; Y Morishima; M Kasai; T Chou; K Yoshida; T Ohno; F Mizorogi; N Uike; T Sai; M Taniwaki; S Ikeda; K Tobinai Journal: Leuk Lymphoma Date: 2000-08
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: S Rottey; D Loose; L Vakaet; C Lahorte; H Vermeersch; S Van Belle; C Van de Wiele Journal: Q J Nucl Med Mol Imaging Date: 2007-06 Impact factor: 2.346
Authors: Lieselot Brepoels; Sigrid Stroobants; Peter Vandenberghe; Karoline Spaepen; Patrick Dupont; Johan Nuyts; Guy Bormans; Luc Mortelmans; Gregor Verhoef; Christiane De Wolf-Peeters Journal: J Nucl Med Date: 2007-03 Impact factor: 10.057
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: K Spaepen; S Stroobants; P Dupont; P Vandenberghe; J Thomas; T de Groot; J Balzarini; C De Wolf-Peeters; L Mortelmans; G Verhoef Journal: Ann Oncol Date: 2002-09 Impact factor: 32.976
Authors: Bryan A Smith; Shuzhang Xiao; William Wolter; James Wheeler; Mark A Suckow; Bradley D Smith Journal: Apoptosis Date: 2011-07 Impact factor: 4.677
Authors: M De Saint-Hubert; M Bauwens; N Deckers; M Drummen; K Douma; P Granton; G Hendrikx; D Kusters; J Bucerius; C P M Reutelingsperger; F M Mottaghy Journal: Mol Imaging Biol Date: 2014-04 Impact factor: 3.488
Authors: Monique R Bernsen; Pieter E B Vaissier; Roel Van Holen; Jan Booij; Freek J Beekman; Marion de Jong Journal: Eur J Nucl Med Mol Imaging Date: 2014-05 Impact factor: 9.236